Aydin Huseynov
Stock Analyst at Ladenburg Thalmann
(0.68)
# 4,048
Out of 5,182 analysts
58
Total ratings
32%
Success rate
-29.28%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Aydin Huseynov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELTX Elicio Therapeutics | Initiates: Buy | $20 | $11.69 | +71.09% | 1 | Apr 15, 2026 | |
| IKT Inhibikase Therapeutics | Initiates: Buy | $4 | $1.88 | +112.77% | 1 | Mar 4, 2026 | |
| AKTX Akari Therapeutics, | Initiates: Buy | $40 | $5.80 | +589.66% | 1 | Jan 5, 2026 | |
| ARDX Ardelyx | Assumes: Buy | $11 | $5.95 | +84.87% | 1 | Mar 7, 2025 | |
| URGN UroGen Pharma | Assumes: Buy | $31 | $24.11 | +28.58% | 1 | Feb 19, 2025 | |
| MRKR Marker Therapeutics | Maintains: Buy | $11 → $19 | $1.40 | +1,257.14% | 2 | Oct 21, 2024 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $12 → $21 | $16.08 | +30.60% | 3 | Sep 16, 2024 | |
| CMPX Compass Therapeutics | Upgrades: Buy | $5 | $5.03 | -0.60% | 2 | Sep 16, 2024 | |
| ACRV Acrivon Therapeutics | Upgrades: Buy | $16 | $1.91 | +737.70% | 3 | Sep 16, 2024 | |
| CLDI Calidi Biotherapeutics | Initiates: Buy | $120 | $0.23 | +52,997.35% | 1 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $25 | $35.27 | -29.12% | 2 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $54.37 | - | 3 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10,000 | $3.30 | +302,921.12% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $1.44 | +386.11% | 1 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $5.38 | +85.87% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $16.40 | +265.85% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $6 | $1.28 | +368.75% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $4.41 | +126.76% | 3 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $375 → $240 | $2.08 | +11,438.46% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $104 → $182 | $1.79 | +10,067.60% | 2 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Speculative Buy | $4,500 → $2,000 | $2.98 | +67,014.09% | 1 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $10.52 | - | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.34 | - | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $8.90 | +135.96% | 1 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10,500 | $5.70 | +184,110.53% | 1 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $1.74 | +2,026.44% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $300 | $91.68 | +227.23% | 3 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $751.57 | - | 6 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $89 | $94.65 | -5.97% | 2 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | n/a | $127.68 | - | 1 | Sep 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $336 | $1.15 | +29,117.39% | 1 | May 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $3.79 | +374.93% | 1 | Mar 19, 2020 |
Elicio Therapeutics
Apr 15, 2026
Initiates: Buy
Price Target: $20
Current: $11.69
Upside: +71.09%
Inhibikase Therapeutics
Mar 4, 2026
Initiates: Buy
Price Target: $4
Current: $1.88
Upside: +112.77%
Akari Therapeutics,
Jan 5, 2026
Initiates: Buy
Price Target: $40
Current: $5.80
Upside: +589.66%
Ardelyx
Mar 7, 2025
Assumes: Buy
Price Target: $11
Current: $5.95
Upside: +84.87%
UroGen Pharma
Feb 19, 2025
Assumes: Buy
Price Target: $31
Current: $24.11
Upside: +28.58%
Marker Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $11 → $19
Current: $1.40
Upside: +1,257.14%
Corvus Pharmaceuticals
Sep 16, 2024
Maintains: Buy
Price Target: $12 → $21
Current: $16.08
Upside: +30.60%
Compass Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $5
Current: $5.03
Upside: -0.60%
Acrivon Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $16
Current: $1.91
Upside: +737.70%
Calidi Biotherapeutics
Jun 27, 2024
Initiates: Buy
Price Target: $120
Current: $0.23
Upside: +52,997.35%
May 14, 2024
Maintains: Buy
Price Target: $24 → $25
Current: $35.27
Upside: -29.12%
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $54.37
Upside: -
Feb 8, 2024
Initiates: Buy
Price Target: $10,000
Current: $3.30
Upside: +302,921.12%
Dec 27, 2023
Initiates: Buy
Price Target: $7
Current: $1.44
Upside: +386.11%
Oct 10, 2023
Initiates: Buy
Price Target: $10
Current: $5.38
Upside: +85.87%
Sep 22, 2023
Initiates: Buy
Price Target: $60
Current: $16.40
Upside: +265.85%
Aug 14, 2023
Maintains: Buy
Price Target: $10 → $6
Current: $1.28
Upside: +368.75%
Jun 5, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $4.41
Upside: +126.76%
May 16, 2023
Maintains: Buy
Price Target: $375 → $240
Current: $2.08
Upside: +11,438.46%
Apr 28, 2023
Maintains: Buy
Price Target: $104 → $182
Current: $1.79
Upside: +10,067.60%
Apr 4, 2023
Maintains: Speculative Buy
Price Target: $4,500 → $2,000
Current: $2.98
Upside: +67,014.09%
Nov 4, 2022
Downgrades: Neutral
Price Target: n/a
Current: $10.52
Upside: -
Aug 23, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.34
Upside: -
Jul 13, 2022
Initiates: Buy
Price Target: $21
Current: $8.90
Upside: +135.96%
May 6, 2022
Initiates: Buy
Price Target: $10,500
Current: $5.70
Upside: +184,110.53%
May 2, 2022
Initiates: Buy
Price Target: $37
Current: $1.74
Upside: +2,026.44%
Nov 8, 2021
Upgrades: Buy
Price Target: $300
Current: $91.68
Upside: +227.23%
Nov 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $751.57
Upside: -
Jul 20, 2021
Upgrades: Buy
Price Target: $89
Current: $94.65
Upside: -5.97%
Sep 30, 2020
Initiates: Hold
Price Target: n/a
Current: $127.68
Upside: -
May 21, 2020
Initiates: Buy
Price Target: $336
Current: $1.15
Upside: +29,117.39%
Mar 19, 2020
Initiates: Buy
Price Target: $18
Current: $3.79
Upside: +374.93%